Working… Menu
Trial record 6 of 415 for:    Gonadotrophin, Chorionic AND Choriogonadotropin Alfa

Human Chorionic Gonadotropin Supplementation Prior to In-vitro Fertilization Treatment in Poor Responders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01205009
Recruitment Status : Unknown
Verified September 2010 by Hadassah Medical Organization.
Recruitment status was:  Not yet recruiting
First Posted : September 20, 2010
Last Update Posted : March 2, 2011
Information provided by:
Hadassah Medical Organization

Brief Summary:
In an era of delayed fertility plans, there is increasing need for fertility treatment in older women with poor response. Human chorionic gonadotropin (hCG) supplementation prior to treatment, as a thecal stimulant, may improve folliculogenesis and ovarian response.

Condition or disease Intervention/treatment Phase
Infertility Drug: Ovitrelle Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : April 2011
Estimated Primary Completion Date : March 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Ovitrelle supplemantation
The women will be given 250 mcg of Ovitrelle prior to their IVF cycle
Drug: Ovitrelle
One dose of Ovitrelle 250 mcg

No Intervention: no Ovitrelle supplementation

Primary Outcome Measures :
  1. number of oocytes retrieved [ Time Frame: 1 month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • women >39 years on IVF treatment

Exclusion Criteria:

  • polycystic ovary syndrome
  • Any allergy to injection of human chorionic gonadotropin before

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01205009

Layout table for location contacts
Contact: Mushira Aboo Dia, , MD
Contact: Hadas Lemberg, PhD 00 972 2 6777572

Layout table for location information
Hadassah Medical Center Not yet recruiting
Jerusalem, Israel
Contact: Arik Tzukert, DMD    0097226776095   
Contact: Mushira Aboo Dia, MD    0097226776425   
Sponsors and Collaborators
Hadassah Medical Organization
Layout table for investigator information
Principal Investigator: Mushira Aboo Dia, MD Hadassah Medical Center

Layout table for additonal information
Responsible Party: Arik Tzukert, Hadassah Medical Center Identifier: NCT01205009     History of Changes
Other Study ID Numbers: hCGpoorresp-HMO-CTIL
First Posted: September 20, 2010    Key Record Dates
Last Update Posted: March 2, 2011
Last Verified: September 2010
Keywords provided by Hadassah Medical Organization:
in-vitro fertilization
poor responders
human chorionic gonadotropin
Fertility Agents, Female
Additional relevant MeSH terms:
Layout table for MeSH terms
Genital Diseases, Male
Genital Diseases, Female
Chorionic Gonadotropin
Reproductive Control Agents
Physiological Effects of Drugs